Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study-Reference-Cited by-同舟云学术

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Published:2019-03 Issue:3 Volume:30 Page:397-404
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Adams S.,Schmid P.,Rugo H.S.,Winer E.P.,Loirat D.,Awada A.,Cescon D.W.,Iwata H.,Campone M.,Nanda R.,Hui R.,Curigliano G.,Toppmeyer D.,O’Shaughnessy J.,Loi S.,Paluch-Shimon S.,Tan A.R.,Card D.,Zhao J.,Karantza V.,Cortés J.

Funder

Merck Sharp & Dohme Corp.

Merck & Co., Inc.

Kenilworth

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/3/397/28255129/mdy517.pdf

Reference20 articles.

1. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients;Miles;Ann Oncol,2013

2. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial;Yardley;Ann Oncol,2018

3. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation;Robson;N Engl J Med,2017

4. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation;Litton;N Engl J Med,2018

5. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

Cited by 514 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarker-based immunotherapy in breast cancer;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Evolving immunotherapeutic solutions for triple-negative breast carcinoma;Cancer Treatment Reviews;2024-11

3. A β-1,3/1,6-glucan enhances anti-tumor effects of PD1 antibody by reprogramming tumor microenvironment;International Journal of Biological Macromolecules;2024-11

4. Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment;Cancer Drug Resistance;2024-09-13

5. Clinicopathological features, treatment patterns, and survival outcomes among Syrian patients with advanced breast cancer;Frontiers in Oncology;2024-09-12